Latest News

• Expanded Access Program for gallium maltolate (GaM) Now Open        

  We're glad to announce the FDA recently approved the Expanded Access Program (EAP) for gallium maltolate, an investigational therapy for glioblastoma. The EAP details can be found here and our webinar on the therapy is available here. If you are interested in participating, please email eap@imagingbiometrics.com.
  
  The Musella Foundation gave a grant to help get the EAP started, but our grant covers only part of the program costs. Patients will still be charged a portion of the costs. If any organizations or individuals want to help us with further funding in order to make the EAP free for patients, please contact me! Donations directly to the fund can be made here.

  
  
• Musella Foundation Is Now Accepting Cryptocurrency Donations        

  We're proud to announce we can now accept cryptocurrency donations, including Bitcoin, USD Coin, and Ethereum!

  
  
• Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022        

  Tumor Treating Fields demonstrated good tolerability across >25,000 users, and the safety profile was consistent across subgroups (age, sex, and diagnosis). The most common treatment-related adverse events were skin reactions (43%), electric sensation (tingling; 14%) and heat sensation (warmth; 12%). Most treatment-related adverse events were manageable localized, non-serious skin events.